RUISHUN BIO

Ruishun Bio was established in February 2012, focusing on the development of off-the-shelf universal DNT immune cells. A complete cell production, preparation, and quality control system has been established, and the pipeline for relapsed and refractory acute myeloid leukemia has entered clinical phase I, making it the world's first non-gene editing general-purpose tumor immune cell product . The company will further expand the indication scope of DNT cells on the basis of continuous optimization of the existing process, so as to solve the unmet clinical needs with better efficacy.